Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): A randomised, double-blind, placebo-controlled phase 3 study

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 6, 2014, Pages 455-463

  Sjouke, Barbara ^a   Langslet, Gisle ^b   Ceska, Richard ^c   Nicholls, Stephen J ^d,e   Nissen, Steven E ^d   Öhlander, Maria ^f   Ladenson, Paul W ^g   Olsson, Anders G ^h   Hovingh, G Kees ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c CHARLES UNIVERSITY   (Czech Republic)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f Karo Bio   (Sweden)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h Stockholm Heart Center   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; EPROTIROME; GAMMA GLUTAMYLTRANSFERASE; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; THYROXINE; 3-((3,5-DIBROMO-4-(4-HYDROXY-3-(1-METHYLETHYL)PHENOXY)PHENYL)AMINO)-3-OXOPROPANOIC ACID; ANILIDE; APOLIPOPROTEIN B100; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD LEVEL; BURSITIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLAEMIA; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SYNDROME DELINEATION; TREATMENT DURATION; AFRICA; ANALYSIS OF VARIANCE; ASIA; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; EUROPE; HYPERLIPOPROTEINEMIA TYPE II; LIVER; METABOLISM; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

AFRICA; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANILIDES; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; ASIA; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG-INDUCED LIVER INJURY; EUROPE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84901591020     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70006-3     Document Type: Article

References (32)

1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013, published online Aug 15. 10.1093/eurheartj/eht273.
2. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
3. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209:189-194.
4. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
5. Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010, 5:e9220.
6. Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WM Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995, 155:1490-1495.
7. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000, 10:803-808.
8. Mason R, Hunt H, Hurxthal L Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance. NEJM 1930, 203:1273-1278.
9. Stamler J The coronary drug project-findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977, 82:52-75.
10. Sherman SI, Ladenson PW Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 1992, 75:901-905.
11. Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 2010, 95:1349-1354.
12. Tancevski I, Eller P, Patsch JR, Ritsch A The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs 2009, 10:912-918.
13. Shiohara H, Nakamura T, Kikuchi N, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor beta (TRbeta) agonists for the treatment of dyslipidemia. Bioorg Med Chem 2012, 20:3622-3634.
14. Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008, 105:663-667.
15. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. NEJM 2010, 362:906-916.
16. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991, 303:893-896. Risk of fatal coronary heart disease in familial hypercholesterolaemia.
17. Walma EP, Visseren FL, Jukema JW, Kastelein JJ, Hoes AW, Stalenhoef AF The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board. Ned Tijdschr Geneeskd 2006, 150:18-23.
18. Strisower B, Gofman JW, Galioni E, Rubinger JH, OBrien GW, Simon A Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels. J Clin Endocrinol Metab 1955, 15:73-80.
19. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA 1972, 220:996-1008. The coronary drug project.
20. Galioni EF, Gofman JW, Guzvich P, Pouteau J, Rubinger JH, Strisower B Long-term effect of dried thyroid on serum-lipoprotein and serum-cholesterol levels. Lancet 1957, 272:120-123.
21. Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005, 102:10297-10302.
22. Ito BR, Zhang BH, Cable EE, et al. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 2009, 156:454-465.
23. Lin JZ, Martagon AJ, Hsueh WA, et al. Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 2012, 153:6136-6144.
24. Bakker O, Hudig F, Meijssen S, Wiersinga WM Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 1998, 249:517-521.
25. Pearce EN Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012, 97:326-333.
26. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994, 93:2758-2763.
27. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
28. McDonnell ME, Braverman LE Drug-related hepatotoxicity. NEJM 2006, 354:2191-2193.
29. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
30. Graham DJ, Drinkard CR, Shatin D Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003, 98:175-179.
31. Bellosta S, Paoletti R, Corsini A Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109:III50-III57.
32. Sweeney ME, Johnson RR Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2007, 3:441-450.